首页 | 本学科首页   官方微博 | 高级检索  
检索        

腹腔热灌注化疗联合顺铂化疗方案治疗晚期卵巢癌的临床疗效及其对血清癌胚抗原、糖类抗原125的影响
引用本文:肖燕,侯桂兰.腹腔热灌注化疗联合顺铂化疗方案治疗晚期卵巢癌的临床疗效及其对血清癌胚抗原、糖类抗原125的影响[J].临床合理用药杂志,2021,14(6):16-17,20.
作者姓名:肖燕  侯桂兰
作者单位:423000 湖南省郴州市第一人民医院;423000 湖南省郴州市第一人民医院
摘    要:目的探讨腹腔热灌注化疗联合顺铂化疗方案治疗晚期卵巢癌的临床疗效及其对血清癌胚抗原(CEA)、糖类抗原125(CA125)的影响。方法选取郴州市第一人民医院2018—2019年收治的晚期卵巢癌患者122例,依据双盲法分为参照组与联合组,各61例。参照组予以顺铂化疗方案,联合组在参照组基础上予以腹腔热灌注化疗。比较2组临床疗效,治疗前后肿瘤标志物(CEA、CA125),并观察2组毒副作用发生情况。结果联合组临床疗效优于参照组(P<0.05)。治疗前,2组CA125、CAE比较,差异无统计学意义(P>0.05);治疗后,联合组CA125、CAE低于参照组(P<0.05)。联合组毒副作用发生率低于参照组(P<0.05)。结论腹腔热灌注化疗联合顺铂化疗方案治疗晚期卵巢癌的临床疗效确切,可有效减小病灶,并改善预后,且安全性较高。

关 键 词:卵巢癌  腹腔热灌注化疗  顺铂  治疗结果  癌胚抗原  糖类抗原125

Clinical effect and impact on serum carcinoembryonic antigen and carbohydrate antigen 125 of intraperitoneal hyperthermic perfusion chemotherapy combined with cisplatin chemotherapy on advanced ovarian cancer
XIAO Yan,HOU Guilan.Clinical effect and impact on serum carcinoembryonic antigen and carbohydrate antigen 125 of intraperitoneal hyperthermic perfusion chemotherapy combined with cisplatin chemotherapy on advanced ovarian cancer[J].Chinese Journal of Clinical Rational Drug Use,2021,14(6):16-17,20.
Authors:XIAO Yan  HOU Guilan
Institution:(Chenzhou First People’s Hospital,Chenzhou 423000,China)
Abstract:Objective To investigate the clinical effect and impact on serum carcinoembryonic antigen(CEA) and carbohydrate antigen 125(CA125)of intraperitoneal hyperthermic perfusion chemotherapy combined with cisplatin chemotherapy on advanced ovarian cancer.Methods A total of 122 cases of patients with advanced ovarian cancer were selected from 2018 to 2019 year in Chenzhou First People’s Hospital,which were divided into reference group and combined group according to double-blind method,61 cases in each group.The reference group was given cisplatin chemotherapy,the combined group was given intraperitoneal hyperthermic perfusion chemotherapy on the basis of the reference group.Clinical efficacy,tumor markers(CEA,CA125) before and after treatment were compared between the two groups,and the side effects incidence of adverse reactions were observed.Results The clinical efficacy of the combined group was better than reference group(P<0.05).Before treatment,there was no significant difference in CA125 and CAE between the two groups(P>0.05).After treatment,the combined group of CA125 and CAE were lower than reference group(P<0.05).The incidence rate of toxic and side effects in the combined group was lower than reference group(P<0.05).Conclusion Intraperitoneal hyperthermic perfusion chemotherapy combined with cisplatin chemotherapy have an exact clinical effect for advanced ovarian cancer,which can effectively reduce the focus and improve the prognosis,and with high safety.
Keywords:Oophoroma  Intraperitoneal hyperthermic perfusion chemotherapy  Cisplatin  Treatment outcome  Carcinoembryonic antigen  Carbohydrate antigen 125
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号